Open Label Study of Long Term Safety Evaluation of Alirocumab
Status:
Completed
Trial end date:
2017-06-30
Target enrollment:
Participant gender:
Summary
Primary Objective:
To assess the long-term safety of alirocumab (SAR236553/REGN727) when added to lipid-lowering
therapy in participants with heterozygous familial hypercholesterolemia (heFH) who had
completed EFC12492 (NCT01623115), R727-CL-1112 (NCT01709500), EFC12732 (NCT01617655) and
LTS11717 (NCT01507831).
Secondary Objectives:
- To evaluate the long-term efficacy of alirocumab on lipid parameters.
- To evaluate the long-term immunogenicity of alirocumab.